{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:11:19Z","timestamp":1791461479638,"version":"4.3.4"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006485","name":"National Institute for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109934","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:28:48Z","timestamp":1677457728000},"page":"109934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations"],"prefix":"10.1016","volume":"117","author":[{"given":"Mona Sadat","family":"Mirtaleb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Falak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Heshmatnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Bakhshandeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramezan Ali","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoorieh","family":"Soleimanjahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Zolfaghari Emameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"472","key":"10.1016\/j.intimp.2023.109934_b0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.12688\/f1000research.52061.1","article-title":"Negative sentiment towards COVID-19 vaccines: A comparative study of USA and UK social media posts before vaccination rollout","volume":"10","author":"Lappeman","year":"2021","journal-title":"F1000Research"},{"key":"10.1016\/j.intimp.2023.109934_b0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12575-020-00121-9","article-title":"Combination of biodata mining and computational modelling in identification and characterization of ORF1ab Polyprotein of SARS-CoV-2 Isolated from Oronasopharynx of an Iranian Patient","volume":"22","author":"Zolfaghari Emameh","year":"2020","journal-title":"Biol. Proced. Online"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/pharmrev.120.000285","article-title":"Immunology and technology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines","volume":"74","author":"Pecetta","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2023.109934_b0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12575-020-00127-3","article-title":"Expansion of Single Cell Transcriptomics Data of SARS-CoV Infection in Human Bronchial Epithelial Cells to COVID-19","volume":"22","author":"Zolfaghari Emameh","year":"2020","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.intimp.2023.109934_b0025","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3389\/fimmu.2020.585354","article-title":"A Review of the Progress and Challenges of Developing a Vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109934_b0030","doi-asserted-by":"crossref","first-page":"e0237691","DOI":"10.1371\/journal.pone.0237691","article-title":"Mask or no mask for COVID-19: A public health and market study","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0035","doi-asserted-by":"crossref","first-page":"e10163","DOI":"10.1002\/mds3.10163","article-title":"How effective is a mask in preventing COVID-19 infection?","volume":"4","author":"Wang","year":"2021","journal-title":"Medical devices & sensors"},{"issue":"3","key":"10.1016\/j.intimp.2023.109934_b0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/ice.2020.245","article-title":"Why people failed to adhere to COVID-19 preventive behaviors? Perspectives from an integrated behavior change model","volume":"42","author":"Chan","year":"2021","journal-title":"Infect. Control Hosp. Epidemiol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-022-01814-3","article-title":"Efficacy and practice of facemask use in general population: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"8","key":"10.1016\/j.intimp.2023.109934_b0050","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3390\/su14084766","article-title":"COVID-19 Pandemic: New Prevention and Protection Measures","volume":"14","author":"Cirrincione","year":"2022","journal-title":"Sustainability"},{"key":"10.1016\/j.intimp.2023.109934_b0055","first-page":"E013","article-title":"Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi=","volume":"43","author":"Zhang","year":"2020","journal-title":"Chinese journal of tuberculosis and respiratory diseases"},{"key":"10.1016\/j.intimp.2023.109934_b0060","doi-asserted-by":"crossref","first-page":"e63704","DOI":"10.7554\/eLife.63704","article-title":"Quantifying the impact of quarantine duration on COVID-19 transmission","volume":"10","author":"Ashcroft","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.intimp.2023.109934_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173890","article-title":"A review of potential suggested drugs for coronavirus disease (COVID-19) treatment","volume":"895","author":"Tarighi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2023.109934_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111518","article-title":"Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy","volume":"138","author":"Mirtaleb","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.intimp.2023.109934_b0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jama.2022.0335","article-title":"COVID-19 Therapeutics for nonhospitalized patients","volume":"327","author":"Gandhi","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.109934_b0085","doi-asserted-by":"crossref","unstructured":"Gelfand, A.A. and G. Poland, Migraine treatment and COVID\u201019 vaccines: No cause for concern. 2021, Wiley Online Library.","DOI":"10.1111\/head.14086"},{"issue":"6585","key":"10.1016\/j.intimp.2023.109934_b0090","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1126\/science.abn1755","article-title":"COVID-19 vaccination: The road ahead","volume":"375","author":"Altmann","year":"2022","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2023.109934_b0095","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/oxrep\/grac036","article-title":"Vaccines and the Covid-19 pandemic: lessons from failure and success","volume":"38","author":"Kominers","year":"2022","journal-title":"Oxf. Rev. Econ. Policy"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1473-3099(22)00640-5","article-title":"Hybrid immunity and strategies for COVID-19 vaccination","volume":"23","author":"Hui","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.intimp.2023.109934_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104554","article-title":"Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection","volume":"152","author":"Khorramdelazad","year":"2021","journal-title":"Microb Pathog"},{"key":"10.1016\/j.intimp.2023.109934_b0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coi.2021.07.003","article-title":"COVID-19 vaccines","volume":"71","author":"Ndwandwe","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2023.109934_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA Vaccines in the COVID-19 Pandemic and Beyond","volume":"73","author":"Hogan","year":"2022","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.fmre.2021.01.009","article-title":"SARS-CoV-2 virus: vaccines in development","volume":"1","author":"Huang","year":"2021","journal-title":"Fundamental Research"},{"issue":"17","key":"10.1016\/j.intimp.2023.109934_b0125","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jgg.2021.02.006","article-title":"COVID-19 mRNA vaccines","volume":"48","author":"Huang","year":"2021","journal-title":"J. Genet. Genomics"},{"issue":"4","key":"10.1016\/j.intimp.2023.109934_b0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2023.109934_b0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.intimp.2023.109934_b0150","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.intimp.2023.109934_b0160","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejpb.2008.09.016","article-title":"Current prospects for mRNA gene delivery","volume":"71","author":"Yamamoto","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.intimp.2023.109934_b0165","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.7150\/ijbs.59233","article-title":"mRNA vaccines for COVID-19: what, why and how","volume":"17","author":"Park","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2023.109934_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.intimp.2023.109934_b0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"issue":"5","key":"10.1016\/j.intimp.2023.109934_b0180","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109934_b0185","doi-asserted-by":"crossref","unstructured":"Santos, I.d.A., et al., Antivirals against coronaviruses: candidate drugs for SARS-CoV-2 treatment? Frontiers in microbiology, 2020: p. 1818.","DOI":"10.3389\/fmicb.2020.01818"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"issue":"6511","key":"10.1016\/j.intimp.2023.109934_b0195","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2023.109934_b0200","doi-asserted-by":"crossref","first-page":"e1008762","DOI":"10.1371\/journal.ppat.1008762","article-title":"COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2","volume":"16","author":"Mittal","year":"2020","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13104-020-05439-x","article-title":"Identification and characterization of a silent mutation in RNA binding domain of N protein coding gene from SARS-CoV-2","volume":"14","author":"Zolfaghari Emameh","year":"2021","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.intimp.2023.109934_b0210","doi-asserted-by":"crossref","unstructured":"Wang, Q., et al., Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, 2020. 181(4): p. 894-904. e9.","DOI":"10.1016\/j.cell.2020.03.045"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41182-020-00285-w","article-title":"Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review","volume":"48","author":"Girum","year":"2020","journal-title":"Tropical medicine and health"},{"issue":"7","key":"10.1016\/j.intimp.2023.109934_b0220","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2023.109934_b0225","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"7853","key":"10.1016\/j.intimp.2023.109934_b0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0235","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2023.109934_b0240","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","article-title":"Impact of lipid nanoparticle size on mRNA vaccine immunogenicity","volume":"335","author":"Hassett","year":"2021","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.intimp.2023.109934_b0245","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1006\/bbrc.1997.7749","article-title":"Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins","volume":"240","author":"Nakanishi","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2023.109934_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.589959","article-title":"Advances in lipid nanoparticles for mRNA-based cancer immunotherapy","volume":"8","author":"Guevara","year":"2020","journal-title":"Front. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2023.109934_b0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nano.2013.12.003","article-title":"Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways","volume":"10","author":"Lonez","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"9","key":"10.1016\/j.intimp.2023.109934_b0260","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acsinfecdis.9b00084","article-title":"Mannosylation of LNP results in improved potency for self-amplifying RNA (SAM) vaccines","volume":"5","author":"Goswami","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.intimp.2023.109934_b0265","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/82_2022_259","article-title":"Clinical development of mRNA vaccines: challenges and opportunities","author":"August","year":"2022","journal-title":"mRNA Vaccines"},{"issue":"11","key":"10.1016\/j.intimp.2023.109934_b0270","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","article-title":"Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery","volume":"3","author":"Nogueira","year":"2020","journal-title":"ACS Applied Nano Materials"},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2023.109934_b0280","series-title":"Chimeric Antigen Receptor T Cells","first-page":"87","article-title":"In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development","author":"Miliotou","year":"2020"},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0285","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00018-018-2935-4","article-title":"mRNA as novel technology for passive immunotherapy","volume":"76","author":"Schlake","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2023.109934_b0290","doi-asserted-by":"crossref","unstructured":"O'neill, L.A., D. Golenbock, and A.G. Bowie, The history of Toll-like receptors\u2014redefining innate immunity. Nature Reviews Immunology, 2013. 13(6): p. 453-460.","DOI":"10.1038\/nri3446"},{"key":"10.1016\/j.intimp.2023.109934_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.948770","article-title":"Toll-like receptor signaling in severe acute respiratory syndrome coronavirus 2-induced innate immune responses and the potential application value of toll-like receptor Immunomodulators in patients with coronavirus disease 2019","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109934_b0300","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/gt.2017.5","article-title":"Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems","volume":"24","author":"Guan","year":"2017","journal-title":"Gene Ther."},{"issue":"9","key":"10.1016\/j.intimp.2023.109934_b0305","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2023.109934_b0310","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2023.109934_b0315","article-title":"Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence","author":"Puranik","year":"2021","journal-title":"MedRxiv"},{"issue":"13","key":"10.1016\/j.intimp.2023.109934_b0320","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.intimp.2023.109934_b0325","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1093\/nar\/gkab764","article-title":"Theoretical basis for stabilizing messenger RNA through secondary structure design","volume":"49","author":"Wayment-Steele","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"48","key":"10.1016\/j.intimp.2023.109934_b0330","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2023.109934_b0335","doi-asserted-by":"crossref","unstructured":"Nelson, J., et al., Impact of mRNA chemistry and manufacturing process on innate immune activation. Science advances, 2020. 6(26): p. eaaz6893.","DOI":"10.1126\/sciadv.aaz6893"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"npj Vaccines"},{"issue":"19","key":"10.1016\/j.intimp.2023.109934_b0345","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMc2100362","article-title":"New SARS-CoV-2 variants\u2014clinical, public health, and vaccine implications","volume":"384","author":"Abdool Karim","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2023.109934_b0350","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"10249","key":"10.1016\/j.intimp.2023.109934_b0355","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10240","key":"10.1016\/j.intimp.2023.109934_b0360","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.intimp.2023.109934_b0365","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/infdis\/jiab593","article-title":"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines","volume":"225","author":"Naranbhai","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2023.109934_b0370","unstructured":"COVID, M., Vaccine. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting. December 17, 2020. 2020. 2021."},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0375","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"issue":"9106","key":"10.1016\/j.intimp.2023.109934_b0380","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(05)70317-2","article-title":"Autism, inflammatory bowel disease, and MMR vaccine","volume":"351","author":"Beale","year":"1998","journal-title":"Lancet"},{"issue":"9106","key":"10.1016\/j.intimp.2023.109934_b0385","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(05)70320-2","article-title":"Autism, inflammatory bowel disease, and MMR vaccine","volume":"351","author":"Bedford","year":"1998","journal-title":"Lancet"},{"issue":"9106","key":"10.1016\/j.intimp.2023.109934_b0390","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(05)70316-0","article-title":"Autism, inflammatory bowel disease, and MMR vaccine","volume":"351","author":"Black","year":"1998","journal-title":"Lancet"},{"issue":"9106","key":"10.1016\/j.intimp.2023.109934_b0395","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(98)26012-0","article-title":"Autism, inflammatory bowel disease, and MMR vaccine","volume":"351","author":"Lee","year":"1998","journal-title":"Lancet"},{"issue":"9106","key":"10.1016\/j.intimp.2023.109934_b0400","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(05)70321-4","article-title":"Autism, inflammatory bowel disease, and MMR vaccine","volume":"351","author":"Lindley","year":"1998","journal-title":"Lancet"},{"issue":"9106","key":"10.1016\/j.intimp.2023.109934_b0405","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(05)70318-4","article-title":"Autism, inflammatory bowel disease, and MMR vaccine","volume":"351","author":"O'Brien","year":"1998","journal-title":"Lancet"},{"issue":"9106","key":"10.1016\/j.intimp.2023.109934_b0410","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(05)70319-6","article-title":"Autism, inflammatory bowel disease, and MMR vaccine","volume":"351","author":"Payne","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109934_b0415","series-title":"The pandemic of argumentation","first-page":"125","article-title":"The argumentative potential of doubt: From legitimate concerns to conspiracy theories about COVID-19 vaccines","author":"Mohammed","year":"2022"},{"issue":"8","key":"10.1016\/j.intimp.2023.109934_b0420","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14760584.2021.1949293","article-title":"COVID-19 vaccines: concerns beyond protective efficacy and safety","volume":"20","author":"Lai","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2023.109934_b0425","doi-asserted-by":"crossref","unstructured":"Doerfler, W., Adenoviral Vector DNA-and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome-Are Adenoviral Genes Expressed in Vector-based Vaccines? Virus Res, 2021. 302: p. 198466-198466.","DOI":"10.1016\/j.virusres.2021.198466"},{"key":"10.1016\/j.intimp.2023.109934_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198466","article-title":"Viral Vector DNA-and RNA-Based SARS-CoV-2 Vaccines: Possible Integration into the Human Genome Are Adenoviral Genes Expressed in Vector-based Vaccines?","volume":"302","author":"Doerfler","year":"2021","journal-title":"Virus Res."},{"key":"10.1016\/j.intimp.2023.109934_b0435","doi-asserted-by":"crossref","unstructured":"Zhang, L., et al., SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. bioRxiv, 2020.","DOI":"10.1101\/2020.12.12.422516"},{"issue":"45","key":"10.1016\/j.intimp.2023.109934_b0440","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.15585\/mmwr.mm7145a2","article-title":"Interim recommendations from the Advisory Committee on Immunization Practices for the use of bivalent booster doses of COVID-19 vaccines\u2014United States, October 2022","volume":"71","author":"Rosenblum","year":"2022","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.intimp.2023.109934_b0445","unstructured":"Control, C.f.D. and Prevention, Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. 2021."},{"key":"10.1016\/j.intimp.2023.109934_b0450","doi-asserted-by":"crossref","DOI":"10.1108\/case.kellogg.2016.000261","article-title":"Polio Eradication\u2014Within Our Reach?","author":"Besanko","year":"2017","journal-title":"Kellogg Sch. Manag. Cases"},{"key":"10.1016\/j.intimp.2023.109934_b0455","doi-asserted-by":"crossref","unstructured":"Fleming-Dutra, K.E., et al., Interim recommendations of the Advisory Committee on Immunization Practices for use of Moderna and Pfizer-BioNTech COVID-19 vaccines in children aged 6 months\u20135 years\u2014United States, June 2022. 2022.","DOI":"10.15585\/mmwr.mm7126e2"},{"issue":"3","key":"10.1016\/j.intimp.2023.109934_b0460","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2023.109934_b0465","article-title":"mRNA vaccines: Past, present, future","author":"Karam","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2023.109934_b0470","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109934_b0475","first-page":"e924700","article-title":"An evidence based perspective on mRNA-SARS-CoV-2 vaccine development","volume":"26","author":"Wang","year":"2020","journal-title":"Medical science monitor: international medical journal of experimental and clinical research"},{"key":"10.1016\/j.intimp.2023.109934_b0480","doi-asserted-by":"crossref","unstructured":"The EMBO journalZhao, X., et al., Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. The Lancet Microbe, 2021. 2(10): p. E494.","DOI":"10.1016\/S2666-5247(21)00217-2"},{"key":"10.1016\/j.intimp.2023.109934_b0485","doi-asserted-by":"crossref","unstructured":"Zhang, X.-O., H. Pratt, and Z. Weng, Investigating the potential roles of SINEs in the human genome. Annual Review of Genomics and Human Genetics, 2021. 22: p. pp 199-218.","DOI":"10.1146\/annurev-genom-111620-100736"},{"key":"10.1016\/j.intimp.2023.109934_b0490","doi-asserted-by":"crossref","unstructured":"Desfarges, S. and A. Ciuffi, Viral integration and consequences on host gene expression, in Viruses: essential agents of life. 2012, Springer. p. 147-175.","DOI":"10.1007\/978-94-007-4899-6_7"},{"key":"10.1016\/j.intimp.2023.109934_b0495","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2017.06.005","article-title":"Viruses as vectors of horizontal transfer of genetic material in eukaryotes","volume":"25","author":"Gilbert","year":"2017","journal-title":"Curr. Opin. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0500","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1099\/jgv.0.000738","article-title":"ICTV virus taxonomy profile: Geminiviridae","volume":"98","author":"Zerbini","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0505","first-page":"1","article-title":"Assessment of databases to determine the validity of \u03b2-and \u03b3-carbonic anhydrase sequences from vertebrates","volume":"21","author":"Emameh","year":"2020","journal-title":"BMC Genomics"},{"key":"10.1016\/j.intimp.2023.109934_b0510","doi-asserted-by":"crossref","unstructured":"Emameh, R.Z., S.N. Hosseini, and S. Parkkila, Application of beta and gamma carbonic anhydrase sequences as tools for identification of bacterial contamination in the whole genome sequence of inbred Wuzhishan minipig (Sus scrofa) annotated in databases. Database: the journal of biological databases and curation, 2021. 2021: p. baab029.","DOI":"10.1093\/database\/baab029"},{"issue":"22","key":"10.1016\/j.intimp.2023.109934_b0515","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1128\/JVI.00955-10","article-title":"Widespread horizontal gene transfer from double-stranded RNA viruses to eukaryotic nuclear genomes","volume":"84","author":"Liu","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.56098\/ijvtpr.v2i1.23","article-title":"Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19","volume":"2","author":"Seneff","year":"2021","journal-title":"International Journal of Vaccine Theory, Practice, and Research"},{"issue":"4","key":"10.1016\/j.intimp.2023.109934_b0525","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41577-021-00525-y","article-title":"Are COVID-19 vaccines safe in pregnancy?","volume":"21","author":"Male","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2023.109934_b0530","doi-asserted-by":"crossref","first-page":"e13678","DOI":"10.1111\/eci.13678","article-title":"COVID-19 vaccination in children and university students","volume":"51","author":"Ioannidis","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0535","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.109934_b0540","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/idr13030064","article-title":"COVID-19 vaccine in pregnant and lactating women: a review of existing evidence and practice guidelines","volume":"13","author":"Garg","year":"2021","journal-title":"Infectious disease reports"},{"issue":"12","key":"10.1016\/j.intimp.2023.109934_b0545","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/14760584.2021.1986390","article-title":"COVID-19 vaccination in pregnant and lactating women: a systematic review","volume":"20","author":"Falsaperla","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2023.109934_b0550","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109934_b0555","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2023.109934_b0560","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/bfm.2021.0079","article-title":"Maternal and child symptoms following COVID-19 vaccination among breastfeeding mothers","volume":"16","author":"McLaurin-Jiang","year":"2021","journal-title":"Breastfeed. Med."},{"key":"10.1016\/j.intimp.2023.109934_b0565","doi-asserted-by":"crossref","first-page":"2153532","DOI":"10.1080\/21645515.2022.2153532","article-title":"Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape","author":"Das","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0570","doi-asserted-by":"crossref","DOI":"10.36877\/pmmb.a0000256","article-title":"COVID-19 Booster Vaccines Administration in Different Countries","volume":"4","author":"Thye","year":"2021","journal-title":"Progress In Microbes & Molecular Biology"},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0575","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2213-2600(21)00559-2","article-title":"Omicron variant and booster COVID-19 vaccines","volume":"10","author":"Burki","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2023.109934_b0580","article-title":"Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109934_b0585","doi-asserted-by":"crossref","unstructured":"Lopez Bernal, J., et al., Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N. Engl. j. med, 2021.","DOI":"10.1056\/NEJMoa2108891"},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0590","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/ijerph20021647","article-title":"Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia","volume":"20","author":"Wong","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"3","key":"10.1016\/j.intimp.2023.109934_b0595","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/fvl-2021-0280","article-title":"Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA","volume":"17","author":"Milano","year":"2022","journal-title":"Futur. Virol."},{"key":"10.1016\/j.intimp.2023.109934_b0600","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 vaccination in a large health care organization","author":"Witberg","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0605","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ageing\/afaa274","article-title":"Efficacy and safety of COVID-19 vaccines in older people","volume":"50","author":"Soiza","year":"2021","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0610","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10067-020-05547-w","article-title":"COVID-19 vaccination in immunocompromised patients","volume":"40","author":"Sonani","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0615","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/ijms24020908","article-title":"Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation","volume":"24","author":"Lucca","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2023.109934_b0620","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.intimp.2023.109934_b0625","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/mmi.12738","article-title":"Direct regulation of the pefI-srgC operon encoding the Rck invasin by the quorum-sensing regulator SdiA in S almonella T yphimurium","volume":"94","author":"Abed","year":"2014","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.intimp.2023.109934_b0630","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17508","article-title":"Immune thrombocytopenic purpura after SARS-CoV-2 vaccine","author":"Candelli","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109934_b0635","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.annemergmed.2021.02.011","article-title":"Idiopathic thrombocytopenic purpura and the moderna covid-19 vaccine","volume":"77","author":"Julian","year":"2021","journal-title":"Ann. Emerg. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0640","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2021.04.003","article-title":"Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?","volume":"75","author":"Bril","year":"2021","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109934_b0645","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.06.014","article-title":"Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine","volume":"75","author":"Clayton-Chubb","year":"2021","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109934_b0650","doi-asserted-by":"crossref","first-page":"e244125","DOI":"10.1136\/bcr-2021-244125","article-title":"Guillain-Barr\u00e9 syndrome after COVID-19 vaccination","volume":"14","author":"McKean","year":"2021","journal-title":"BMJ Case Reports CP"},{"issue":"1","key":"10.1016\/j.intimp.2023.109934_b0655","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/keac305","article-title":"COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study","volume":"62","author":"Sen","year":"2023","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.intimp.2023.109934_b0660","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2023.109934_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109530","article-title":"No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing","volume":"36","author":"Smits","year":"2021","journal-title":"Cell Rep"},{"issue":"21","key":"10.1016\/j.intimp.2023.109934_b0670","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105968118","article-title":"Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2023.109934_b0675","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fmolb.2021.635337","article-title":"Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19","volume":"8","author":"Bezbaruah","year":"2021","journal-title":"Front. Mol. Biosci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:59:38Z","timestamp":1761587978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923002540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":135,"alternative-id":["S1567576923002540"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109934","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109934"}}